President Dr. Marc Hedrick gives a company presentation at the 1st Annual Regen Med Investor Day

1. 1st Annual Regen Med Investor Day
Platform to Bedside
Marc Hedrick, MD
President

2. Safe Harbor Statement
This presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. All
statements, other than statements of historical fact, that address activities, events or developments that we
intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements.
Such statements are based upon certain assumptions and assessments made by our management in light of
their experience and their perception of historical trends, current conditions, expected future developments
and other factors they believe to be appropriate.
The forward-looking statements included in this presentation involve known and unknown risks that relate to
Cytori’s future events or future financial performance and the actual results could differ materially from those
discussed in this presentation. Risks and uncertainties that may cause Cytori's actual results to differ
materially from those discussed in the presentation can be found in the "Risk Factors" section of Cytori’s
Form 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. We
would advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filed
with the United States Securities and Exchange Commission for a more detailed description of these risks.
The forward-looking statements contained in this presentation represent Cytori’s estimates and assumptions
only as of the date of this presentation and Cytori undertakes no duty or obligation to update or revise
publicly any forward-looking statements contained in this presentation as a result of new information, future
events or changes in Cytori’s expectations.

3. Cytori Platform: Technology
STEP 1
Harvest patient
tissue (100cc)
STEP 2
Separate &
Process
STEP 3 Technology for cell
Deliver ADRCs to isolation, combination
with other factors,
Same Patient, ~1 hr.
storage and clinical
therapy

4. Cytori Platform: Model
Goal: Leadership in Regenerative Medicine
Research & Regulatory Clinical Commercial
Development Approval Use
Device Safety Self Pay
Basic Approvals
Science
CAPITAL PROFIT
Efficacy Reimbursement
Product Therapeutic
Development Approvals

5. Cytori Platform: Case Study
Radiation
Injury, BARDA
Ischemia &
Japan EU
CV Trials
Gen One EU
Breast Breast
Device Approval Sales
Pilot Pivotal
Other Approvals
& Applications

6. Cytori Cell Therapy:
US Government Contract
Discussions Award 3 Proof-of-concept Objectives 3 Objectives Trigger Option 1 Objective
Begin Announcement Ongoing Option 1 & 3 Triggers Option 2
2010 Fall, 2012 Q1, 2014 Q4, 2015
Cell viability
$32.6 M Option 1
Pre-Award, White Papers,
Animal model POC
Proposal, Negotiation
$45.5M Option 2
Next Gen device feasibility
$4.7M Phase 1 Proof of Concept
$23.4M Option 3
Commercial Acquisition at
BARDA’s Discretion

7. Cytori Platform: Clinical Trials and Studies
43 total: 2 Cytori sponsored trials & 41 investigator studies
USA EU AP
1 23 13
Soft Tissue: 18
Wound: 7
Ischemia: 2 EM
Ortho/Sport: 8
Vital Organ: 8 6
Total: 43